期刊
FUTURE ONCOLOGY
卷 18, 期 9, 页码 1143-1157出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2021-0842
关键词
biomarkers; CDK 4; 6 inhibitors; endocrine resistance; endocrine therapy; HER2-negative breast cancer; hormone receptor (HR) positive; resistance mechanisms
类别
The combination of CDK4/6 inhibitors and endocrine therapy is the preferred treatment for HR-positive, HER2-negative metastatic breast cancer. However, resistance mechanisms and biomarkers predicting the efficacy of CDK4/6 inhibitors are still being studied. This review summarizes the use of CDK4/6 inhibitors in breast cancer and possible approaches to overcome resistance.
Hormone receptor (HR)-positive, HER2-negative tumors represent the most common form of metastatic breast cancer (MBC), and endocrine therapy has been the mainstay treatment for several decades. Recently, a novel drug class called CDK4/6 inhibitors in combination with endocrine therapy have remarkably improved the outcome of patients with HR-positive, HER2-negative MBC by targeting the cell cycle machinery and overcoming aspects of endocrine resistance. Several potential cell-cycle-specific and nonspecific mechanisms of resistance to CDK4/6 inhibitors have been reported in recent studies. This review discusses potential resistance mechanisms to CDK4/6 inhibitors, the use of biomarkers to guide treatment for HR-positive, HER2-negative MBC and possible approaches to overcome resistance to CDK4/6 inhibitors. Plain language summary Approximately 70% of breast cancers are hormone receptor (HR)-positive. A CDK4/6 inhibitor combined with endocrine therapy is the first-line standard of care for patients with HR-positive, HER-2 negative advanced breast cancer. Markers to predict the efficacy of CDK4/6 inhibitors in HR-positive, HER2-negative advanced breast cancer are limited. In this review, we summarize the use of CDK4/6 inhibitors in breast cancer, as well as possible approaches to overcome resistance to CDK4/6 inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据